Gordon, we are in the initial phase of market penetration, not yet at the peak of full commercialisation.
Being approved in over 30 countries is a foundational step. It's about establishing a presence and trust in the global market, which is a lengthy but essential process in the medical field.
This phase is more about strategic positioning than immediate high sales figures.
We must also consider the nature of the biotech industry. Building a market, especially in medical devices, involves complex regulatory processes and establishing key relationships with healthcare providers. These efforts take time but are vital for long-term success and sustainable sales growth.
So, while the current sales figures might seem modest, they are part of a larger, more strategic plan aimed at future growth and market dominance.
Patience and strategic foresight are key at this juncture.
..
OSL Price at posting:
0.7¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)